Clinical Investigation on Gouqi Fushen Pills for Chronic Nephritis

Di ZOU1,a, Cheng-ji CUI2, Yin-ping WANG3, Shou-lin ZHANG4,b,*

1,2,3,4Nephrology department, the Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, Jilin province, China.130021.
a,aggiezou@163.com , b,shoulin-z@163.com

Keywords: Gouqi fushen pills, Chronic nephritis, Clinical investigation

Abstract. Purpose:Observe the effectiveness and security of Gouqi fushen pills treating chronic nephritis. Method:Randomly divide 230 patients with chronic glomerular nephritis into two groups, treatment group and comparison group, each of 115 cases. Both groups orally take benazepril hydrochloride 10mg once a day, while treatment group orally takes a gouqi fushen pill three times a day, in a three-month period. Observe before and after treatment symptoms of both groups, as well as their 24h quantitation of urine protein, counting of urine RBC, and function changes of liver and kidney. Result: (1).5 drop-outs in treatment group, and 12 in comparison group, with the respective total effective rate of 83.64% and 47.57%. The digital difference, according to statistics, has a statistical significance(\(P<0.01\)). (2). Patients in treatment group have seen obvious alleviation of symptoms of osphyalgia, lack in strength and feverish palms and soles (\(P<0.05\)), while comparison group haven’t (\(P>0.05\)). (3). Both groups have a distinct reduction in their 24h quantitation of urine protein and counting of urine RBC,with treatment group reduction higher than comparison group(\(P<0.05\)). (4). Neither group has significant change in liver and kidney functions. Conclusion: Gouqi fushen pills are more effectively conducive than benazepril hydrochloride to cut down patients’ 24h quantitation of urine protein and counting of urine RBC. Also the pills can abate patients’ suffer from osphyalgia, lack in strength and feverish palms and soles.

Introduction

Chronic glomerular nephritis, abbreviated as chronic nephritis, is a glomerular disease performing clinically as hematuresis,proteinuria,hydronecus and hypertension, with which about one third patients progress to ESRD after 10 years’ paroxysm[1]. Traditional Chinese medicine may have prominent efficacy for chronic nephritis, but as there is a lack of patent prescription, it mainly depends on decoction therapies. Gouqi fushen pills, developed by Dr. Zhen-chang Zhao, a prestigious professor of traditional Chinese medicine, have been eminent in efficacy since it first appeared to treat chronic nephritis over 20 years ago. To further verify the pills’ effectiveness and security, we have set up this investigation.

Materials and Methods

Case Source

All 230 cases were chosen from both outpatients and inpatients of affiliated hospital of Changchun University of Chinese Medicine, dating from Oct. to Dec. 2014. They were randomly divided two groups, each of 115 cases,out of which the treatment
group had 60 male and 55 female patients aged from 16 to 65, with comparison group having 56 male and 59 female patients aged from 19 to 68. To make it more explicit, the average age of both group was 42.8±9.2 and 43.6±10.3 respectively, with average disease course of 8.6±1.82 and 7.8±1.69 years, and a number of 45 versus 43 patients that had hypertension. Generally there were no remarkable difference in sexuality, age, disease course or patients’ condition ($P>0.05$).

**Diagnosing Criterion**

1) Western medicine diagnosis standard of chronic glomerular nephritis is according to <Nephrology>3rd edition [2]: urine abnormal RBC proportion over 70% in both continuous microscopic hematuria and/or gross hematuria. Normal renal function, with or without a small amount of 24h proteinuria no more than 1.0g.

2) Belong to deficiency of spleen and kidney, with a damp heat and blood stasis. (According to the standards of TCM "Guiding Principles for New Traditional Medicine Clinical Investigation"[3].

3) Blood pressure controlled under 130/80mmHg.

4) aged between 16 and 70.

**Elimination Criterion**

1) patients with hematuria or proteinuria caused by secondary glomerulopathy like purpura nephritis or lupus nephritis, urinary infections, acute post-infectious glomerular nephritis, hereditary renal diseases, syndrome of osphalgia and hematuria, idiopathic hypercalcuiuria or athlete nephritis. 2) patients with severe organ diseases in heart, brain, liver or lung. 3) pregnant or lactating women, 4) lunatics.

**Grouping and Treatment Methods**

Randomly divide 230 patients with chronic glomerular nephritis into two groups, treatment group and comparison group, each of 115 cases. Both groups orally take benazepril hydrochloride 10mg once a day in a three-month period, provided by Beijing Novartis Pharma Ltd, while treatment group orally takes a gouqi fushen pill three times a day in a three-month period provided as Changchun healthcare medicine (96) No.1413 by manufacturing laboratory of affiliated hospital of Changchun University of Chinese Medicine. Patients should take anti-hypertensive calcium antagonist drugs if their blood pressure stays above 130/80mmHg.

**Observing Index**

compare the before and after treatment figures in integral of syndrome, 24h quantitation of urine protein, counting of urine RBC, and function changes of liver and kidney.

**Efficacy Judging Method**

**Efficacy Judging Criterion.** Clinical control, excellence, efficiency and futility, according to "Guiding Principles for New Traditional Medicine Clinical Investigation" [3]. Use gradational scoring method to observe before and after treatment changes in traditional medicine syndrome, as following details in table 1.
Table 1  Gradational Scoring Criterion for Syndrome

<table>
<thead>
<tr>
<th>item</th>
<th>Lumbar spine pain</th>
<th>fatigue</th>
<th>feverish palms and soles</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 points</td>
<td>none</td>
<td>none</td>
<td>none</td>
</tr>
<tr>
<td>2 points</td>
<td>Occasional or after exhaustion</td>
<td>Occasional, slight, Not resistant to labor</td>
<td>At times</td>
</tr>
<tr>
<td>4 points</td>
<td>A dull pain relief after rest</td>
<td>Manual labor insisting</td>
<td>Need to expose hands and feet</td>
</tr>
<tr>
<td>6 points</td>
<td>Obvious pain, Can’t stand or walk long, action affected</td>
<td>Fatigue after normal actions, even normal daily life Consistent fatigue, Can’t complete daily activity</td>
<td>Want to touch Cool things</td>
</tr>
</tbody>
</table>

Evaluation Criterion for Syndrome Efficacy. Adopt Nimodiping method to calculate integral changes [3].

Statistical Method

Analyze figures with statistical software of SPSS 17.0, illustrating calculated data with ($\bar{x} \pm s$), and counting data with chi-square test, in-group comparison with paired T test, and last but not least, inter-group comparison with independent sample T test, in which $P<0.05$ means a difference with statistical significance.

Results

Overall Efficacy Comparison

The total effective rate of treatment group and comparison group is respectively 83.64% and 47.57%. The digital difference, according to statistics, has a statistical significance ($P<0.01$), as shows in table 2.

Table 2. Overall efficiency figures in both groups (cases)

<table>
<thead>
<tr>
<th>group</th>
<th>n</th>
<th>Clinical control excellence</th>
<th>efficiency</th>
<th>futility</th>
<th>Overall efficiency( % )</th>
</tr>
</thead>
<tbody>
<tr>
<td>treatment</td>
<td>110</td>
<td>6</td>
<td>28</td>
<td>58</td>
<td>18</td>
</tr>
<tr>
<td>comparison</td>
<td>103</td>
<td>2</td>
<td>6</td>
<td>41</td>
<td>54</td>
</tr>
</tbody>
</table>

Note: compare with comparison group, $P<0.01$

Comparison of Gradational Scoring for TCM Syndrome

Comparing with before treatment and after treatment, TCM Syndrome of treatment group have remarkably improved ($P<0.05$), TCM Syndrome of comparison group nearly didn’t change ($P>0.05$). Compared between two group, TCM Syndrome of treatment group is better than comparison group ($P<0.05$). Details follows in table 3.
Pre-post Treatment Figures of Counting of Urine RBC and 24h Quantitation of Urine Protein

Compared with pre-treatment and after treatment, both figures in treatment group have remarkably decreased, which has statistical significance ($P < 0.05$). After treatment, 24h quantitation of urine protein of comparison group decreased ($P < 0.05$), urine RBC of comparison group nearly didn’t change ($P > 0.05$). Compared between two groups, the curative effect of treatment group is better than comparison group ($P < 0.05$). Details follows in table 4.

### Table 4: before and after treatment counting of urine RBC and 24h UTP for two groups

<table>
<thead>
<tr>
<th>Group</th>
<th>RBC</th>
<th>24h UTP</th>
</tr>
</thead>
<tbody>
<tr>
<td>treatment group</td>
<td>before</td>
<td>26.46±6.30</td>
</tr>
<tr>
<td></td>
<td>after</td>
<td>9.20±1.56</td>
</tr>
<tr>
<td>comparison group</td>
<td>before</td>
<td>23.24±3.72</td>
</tr>
<tr>
<td></td>
<td>after</td>
<td>21.17±3.32</td>
</tr>
</tbody>
</table>

Note: compare between treatment group before and after treatment, $^a P<0.05$; compare with comparison group, $^\Delta P<0.05$

### Discussion

As the main clinical performances of chronic glomerular nephritis, hematesis and proteinuria also act as important hazardous factors during renal disease progressive development[4]. When talking about treatment for chronic nephritis, modern medicine still mainly depends on RAAS system blockers, hormones or cellular poisons, which primarily aims at patients with 24h quantitation of urine protein over 1.0g. But for those under 1.0g, or with simple hematesis, there has been a lack of effective means of treatment, meaning that patients of this kind hasn't been taken seriously before. But recent studies have shown that[5], pathological injuries of these patients may not be mild and their conditions may progress at any time. What’s more, Dr. Weibo
Le[6] pointed out that only with a controlled proteinuria under 0.5 g/d can the risk of outcome measures happening be significantly reduced. He also made it clear that microscopic hematuria is related to long-term prognosis, with a 2 times risk of entering outcome measures as each 10 times RBC counts. Accordingly, patients with simple hematuresis or light proteinuria should be given active treatment to prevent pathological deteriorating to ESRD.

As belongs to the ambit of hematuresis, hydroncus and osphyalgia, chronic nephritis is often thought to result from pyretic toxicity harming renal channels due to a damp heat in the bladder. Medical scientists propose a therapy based on cooling for diuresis and hemostasis, but have recurrent attacks after slight efficacy without radical cure. Dr. Zhen-chang Zhao holds a different opinion that the primary cause of chronic nephritis comes from the deficiency of both the spleen and kidney as well as a wet and blood stasis. As kidney functions body fluids while spleen transmits and distributes the fluids, the asthenia of the both may form an interior dampness, which is hard to eradicate with the traditional way of cooling for diuresis and hemostasis. Consequently, to fully heal chronic nephritis and consolidate body, doctors must lay stress on kidney invigorating and spleen strengthening. Based on this theory and his clinical experience for many years, Dr. Zhao has developed the gouqi fushen pills, which has been in application as interior medicine for about 20 years since 1996. The pills are mainly utended to cure hematuresis and proteinuria of chronic nephritis, getting considerable economic benefit. Chinese wolfberry, mild and sweet, is quite useful to reinforce masculine power and to nourish blood, while milkvetch, spleen tonifying and middle warmer strengthening, can reinforce gas and blood and discharge turbidity, both of which contribute to the main prescription of the pills. At the same time, there goes some auxiliary ingredients, such as eclipta, ligustri lucidi and Radix Rehmanniae that also enrich the blood, cogongrass rhizome that clears heat and stanches bleeding, Cirsium japonicum, Cirsium setosum, and Sophorae that also cools the blood. Dr. Zhao believes that pathogen usually intrudes into collateral in protracted disease, and that there will be blood stasis in chronic illness. So he added radix paeoniae, angelica, carthamus tinctorious and heterophyllus to remove blood stasis for a better renal microcirculation, with cortex moutan, cape jasmine and rheum officinale to relax veins, and also some poria cocos to eliminate pathogen. All these make up of the pills, a method of both reinforcement and reduction, contributing to boost the essence of human body.

**Conclusion**

Results shows that the overall efficiency of treatment is impressively higher than comparison group, respectively 83.64% and 47.57% (P<0.01). Also does it have a remarkable result in ameliorating patients’ clinical symptoms and in reducing urine RBC and proteinuria (P<0.01). With this outcome, not only can gouqi fushen pills efficiently decrease patients’ urine RBC and 24h proteinuria, the pills can also relieve them from clinical symptoms like lumbar spine pain, fatigue and feverish palms and soles. Moreover, the higher efficacy than ACEI class effect only together with the harmlessness to liver and renal functions have proved it worthy to further research and development.

**Acknowledgement**

This research was financially supported by project as follows: Jilin Provincial Science & Technology Department (20130206071YY); Jilin Province Education Department
"Twelfth Five Year Plan" science and technology research project (No. 65 of 2014); Jilin Province Administration of traditional Chinese medicine science and technology project (No. 2014-ZC47)

Reference


